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RayagadaA study was conducted at Rayagada district of Odisha, India, among smear-positive tuber-
culosis (TB) patients to determine the resistance pattern to first-line drugs. Sputum sam-
ples were collected from 405 new and 37 previously treated patients and were tested at
Regional Medical Research Centre, Bhubaneswar. Resistance to any anti-tubercular drug
was observed to be 5.2% among new cases and 16.1% among previously treated patients,
while multidrug-resistant tuberculosis (MDR-TB) was found to be 0% in new and 8.1% in
previously treated cases. Such a low level of resistance may be due to the limited use of
TB drugs outside the ongoing program.
 2013 Asian-African Society for Mycobacteriology. Published by Elsevier Ltd. All rights
reserved.Introduction
Globally, the progress of tuberculosis (TB) control activities
has been challenged by the emergence of multidrug-resistant
(MDR) and Extensively Drug Resistant (XDR) strains resulting
in an increased burden to low- and middle-income countries.
MDR-TB prevalence in India varies from 0.5% to 5.7% in newly
diagnosed [1–3] and 11.8–47.1% in retreatment cases [4–7]. An
isolated study conducted in Odisha, India, during 2000–2001
has reported 0.7% of MDR-TB [8]. The present study provides
the current status of drug resistance during the initial phase
of programmatic management of drug-resistant (PMDT) TB
in Rayagada district of Odisha.
Materials and methods
This cross-sectional study was carried out in Rayagada dis-
trict Odisha in collaboration with State and district TB depart-
ments, government of Odisha. The Rayagada district is part of
the KBK, which is a special economic zone of the Statebecause of pan-developmental indices, and a major part of
the population (55.6%) belongs to Scheduled tribes. According
to RNTCP status report 2011, the district reported 1,148 smear-
positive TB cases, of which 936 (81.5%) were newly diagnosed
cases. In this study, suspected pulmonary TB patients attend-
ing all the 18 out of 20 (2 excluded due to very low patient in-
take) Designated Microscopy Centers (DMCs) of the district
whose sputum was found AFB-positive by Ziehl-Neelsen
(ZN) staining were requested to provide additional sputum
samples, preferably two specimens: early morning (EM) and
spot for drug sensitivity testing. However, patients providing
only one specimen, spot or EM, were also processed for cul-
ture. New and previously treated patients were categorized
based on treatment history verified by TB number at DMC le-
vel. Sputum samples were collected in 50 ml falcon tubes to
which equal volumes of Cetylpyridinium chloride–sodium
chloride (CPC–NaCl) was added [9] and kept at room temper-
ature until processed. Samples were processed following
standard method [9] at Regional Medical Research Centre,
Bhubaneswar TB laboratory that conforms to the externalved.
Table 1 – Pattern of primary drug resistance in new and previously treated cases.
Drug resistance pattern New cases, n = 405 Previously treated cases, n = 37 Total n = 442
N %(95% CI) N %(95% CI) N %(95% CI)
Susceptible to all drugs 384 94.8(92.1–96.7) 29 78.4(61.3–89.6) 413 93.4(90.6–95.4)
Resistance to any drug 21 5.2(3.4–7.8) 8 21.6(10.4–38.7) 29 5.6(4.5–9.4)
Resistance to H 10 2.47(1.4–4.5) 2 5.4(1.0–19.5) 12 2.71(1.5–4.8)
Resistance to S 10 2.47(1.4–4.5) 2 5.4(1.0–19.5) 12 2.71(1.5–4.8)
Resistance to S+H 1 0.2(0–1.6) 1 2.7(0.1–15.8) 2 0.5(0.1–1.8)
Resistance to H+R 0 0 2 5.4(1–19.5) 2 0.5(0.1–1.8)
Resistance to S+H+R+E 0 0 1 2.7(0.1–15.8) 1 0.23(0.0–0.0)
MDR 0 0 3 8.1(2.1–23.0) 3 0.7(1.2–2.1)
*95% CI with continuity correction.
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tory (National Institute for Research in Tuberculosis, Chennai)
prior to and during the study period. Deposit specimens were
inoculated into Lowenstein Jensen (LJ) medium, and isolates
were identified by growth rate, colony morphology, para-
nitrobenzoic acid susceptibility, and catalase and niacin tests.
Drug susceptibility testing (DST) was performed by the eco-
nomic version of proportion method for drug concentrations
using streptomycin (S) 4 lg/ml, isoniazid (H) 0.2 lg/ml, rifam-
picin (R) 40 lg/ml, and ethambutol (E) 2 lg/ml. Internal quality
assurance for DST results was performed using two strains:
one susceptible H37Rv strain; and one fully resistant strain
ofMycobacterium tuberculosis provided by NIRT, Chennai. Writ-
ten informed consent was obtained from all the patients after
explaining the details of the procedure and the benefit of the
study. The study protocol was approved by the Ethical Com-
mittee of the Institute.
Results
The study was undertaken in Rayagada district during
the period February 2012 to April 2013. During this study
period 1037 new cases were registered with the district TB
program.
Sputum samples were collected from 518 smear-positive
TB patients who consented and complied with the request
to provide additional sputum specimens. After processing
and inoculation in LJ medium, 442 (85.3%) samples showed
isolates of M. tuberculosis, while 54 cases did not show any
growth, 19 showed contamination and 3 were nontuberculous
mycobacteria (NTM). The age of the 442 patients ranged be-
tween 10 and 70 years (mean ± SD, 36.74 + 13.51, median 36).
Among them 78.7% were males and 91.6% were newly diag-
nosed cases. The age of newly diagnosed cases ranged be-
tween 10 and 67 years (mean ± SD, was 36.4 ± 13.45, median
35), and 37 previously treated cases ranged between 13 and
70 years (mean ± SD, 40.16 ± 13.80, median 40). From the
above 442 isolates resistant to any drug was 5.2% (95% CI,
3.4–7.8) and 21.6% (95% CI, 10.4–38.7) among new and previ-
ously treated cases respectively, Table 1. When each drug
was considered separately, H and S resistance was 2.5%
(95% CI, 1.4–4.5) each for new and 5.4% (95% CI, 1.0–19.5) each
for previously treated cases respectively. Prevalence of MDR-
TB was 0% and 8.1% (95% CI, 2.1–23.0) among new and previ-
ously treated cases. Out of the three MDR-TB patients, two
were females permanently staying in the district and wereHIV negative. The other patient was a male on a transferable
job and he was transferred out of Odisha State, whose HIV
infection status was not known.
Discussion
The study was conducted in a district of Odishawith 40% of its
area covered by forest and home to 55.6% indigenous popula-
tion. In newly diagnosed cases the resistance to the first-line
drugs was observed to be 2.7% for isoniazid or streptomycin
and no resistance to rifampicin or ethambutol. Similar obser-
vations were reported in the earlier study, from another indig-
enous people dominated district inMayurbhanj of Odisha that
reported 2.5% and 3.9% resistance to isoniazid and streptomy-
cin respectively [8]. In comparison with other reported studies
in India [1–3], a low prevalence of MDR-TB was found among
new smear-positive cases in Rayagada district. The observed
8.1% MDR-TB prevalence among previously treated patients
was also lower than the reported prevalence of 11.8–47.1% in
other parts of India [4–7]. This study demonstrates a relatively
low level of overall resistance to first-line anti-tuberculosis
drugs and also a low level of MDR-TB both in new and retreat-
ment cases. Some of the reasons for this low level could be: (i)
the higher treatment success ratewhich has been consistently
above 85% in the district; (ii) limited availability of anti-TB
drugs outside the RNTCP system; and (iii) working of LEPRA
society in the district from the year 2008 to 2012 under SA-
HYOG project for improved case detection, treatment and
awareness among TB patients.
Conclusion
This study indicates that primary drug resistance is low in the
district and suggests that more attention to early detection
and treatment through DOTS can sustain this low level of
resistance to anti-TB drugs for a longer period.
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